Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 135-139

  Wang, Feng ^a   Chen, Lin ^b   Mao, Zhen Biao ^a   Shao, Jian Guo ^b   Tan, Chang ^c   Huang, Wei Da ^c  

^a NANTONG UNIVERSITY   (China)

^b Third People's Hospital of Nantong City   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

A proliferation inducing ligand gene; Lentivirus; Pancreatic cancer; RNA interference; Short hairpin RNA

Indexed keywords

APRIL PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TNFSF13 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; DRUG ANTAGONISM; GENE THERAPY; GENETICS; LENTIVIRINAE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; GENE THERAPY; HUMANS; LENTIVIRUS; MICE; MICE, INBRED BALB C; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 49849098179     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.135     Document Type: Article

References (28)

1. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
2. Cascinu S, Verdecchia L, Valeri N, Berardi R and Scartozzi M: New target therapies in advanced pancreatic cancer. Ann Oncol 5: V148-V152, 2006.
3. Sarkar FH, Banerjee S and Li Y: Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol 224: 326-336, 2007.
4. Vernejoul F, Ghenassia L, Souque A, Lulka H, Drocourt D, Cordelier P, Pradayrol L, Pyronnet S. Buscail L and Tiraby G: Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther 14: 758-767, 2006.
5. Sun L, Cai L, Yu Y, Meng Q, Cheng X, Zhao Y, Sui G and Zhang F: Knockdown of S-phase kinase-associated protein-2 expression in MCF-7 inhibits cell growth and enhances the cytotoxic effects of epirubicin. Acta Biochim Biophys Sin 39: 999-1007, 2007.
6. Hao JH, Gu QL, Liu BY, Li JF, Chen XH, Ji YB, Zhu ZG and Lin YZ: Inhibition of the proliferation of human gastric cancer cells SGC-7901 in vitro and in vivo using Bcl-2 siRNA. Chin Med J 120: 2105-2111, 2007.
7. Bakalova R: RNA interference-about the reality to be exploited in cancer therapy. Methods Find Exp Clin Pharmacol 29: 417-421, 2007.
8. Jazag A, Ijichi H, Kanai F, Imamura T, Guleng B, Ohta M, Imamura J, Tanaka Y, Tateishi K, Ikenoue T, Kawakami T, Arakawa Y, Miyagishi M, Taira K, Kawabe T and Omata M: Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta. Oncogene 24: 662-671, 2005.
9. Imamura T, Kanai F, Kawakami T, Amarsanaa J, Ijichi H, Hoshida Y, Tanaka Y, Ikenoue T, Tateishi K, Kawabe T, Arakawa Y, Miyagishi M, Taira K, Yokosuka O and Omata M: Proteomic analysis of the TGF-beta signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence Smad4 expression. Biochem Biophys Res Commun 318: 289-296, 2004.
10. Delenda C: Lentiviral vectors: Optimization of packaging, transduction and gene expression. J Gene Med 11: S125-S138, 2004.
11. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, Weinberg RA and Novina CD: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9: 493-501, 2003.
12. Matta H, Hozayev B, Tomar R, Chugh P and Chaudhary PM: Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol Ther 2: 206-210, 2003.
13. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D and Tschopp J: APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188: 1185-1190, 1998.
14. Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J and Weller M: APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ 8: 403-410, 2001.
15. Kelly K, Manos E, Jensen G, Nadauld L and Jones DA: APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 60: 1021-1027, 2000.
16. Grimm D and Kay MA: RNAi and gene therapy: A mutual attraction. Hematology Am Soc Hematol Educ Program 2007: 473-481, 2007.
17. Tiscornia G, Singer O and Verma IM: Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc 1: 234-240, 2006.
18. Ducreux M, Boige V, Goere D, Deutsch E, Ezra P, Elias D and Malka D: Pancreatic cancer: from pathogenesis to cure. Best Pract Res Clin Gastroenterol 21: 997-1014, 2007.
19. Talar-Wojnarowska R and Malecka-Panas E: Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 12: 186-193, 2006.
20. Kalled SL, Ambrose C and Hsu YM: The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun 8: 206-242, 2005.
21. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, Rennert PD, Tschopp J and Schneider P: Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201: 1375-1383, 2005.
22. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M and Medema JP: Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 12: 637-648, 2005.
23. Planelles L, Carvalho-Pinto CE, Hardenberg G, Smaniotto S. Savino W, Gomez-Caro R, Alvarez-Mon M, de long J, Eldering E, Martinez AC, Medema J P and Hahne M: APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 6: 399-408, 2004.
24. Batten M, Fletcher C, Ng LG, Groom J, Wheway J, Laabi Y, Xin X, Schneider P, Tschopp J, Mackay CR and Mackay F: TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 172: 812-822, 2004.
25. Mackay F, Schneider P, Rennert P and Browning J: BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 21: 231-264, 2003.
26. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, Tschopp J, Donze O, Le Gal FA and Huard B: Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 109: 331-338, 2007.
27. Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, Holler N, Qian F, Mullen C, Strauch K, Browning JL, Ambrose C and Tschopp J: A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 192, 1677-1684, 2000.
28. Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J and Huard B: The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 80: 697-704, 2006.